摘要
目的研讨糖类抗原(CA199)、甲胎蛋白(AFP)、癌胚抗原(CEA)在诊断原发性肝癌的临床应用价值。方法将洛阳市第八人民医院在2017年6月—2018年6月期间收治的原发病肝癌患者10例与良性肝病患者25例分别设为肝癌组与良性肝病组,并将同期在洛阳市第八人民医院接受健康体检的体检者32人设为对照组。对三组研究对象实施化学发光法检测,比较三组CA199、AFP及CEA水平情况。结果比较发现,肝癌组CA199、AFP及CEA水平分别为(125.42±23.57)U/mL、(821.26±62.46)ng/mL、(865.26±33.87)ng/mL,均高于肝病组与对照组,差异有统计学意义(P<0.05);而CA199、AFP与CEA三项肿瘤标志物联合检测,其灵敏度均高于单独检测,差异有统计学意义(P<0.05)。结论 CA199、AFP与CEA三项肿瘤标志物联合诊断在原发性肝癌中具有较高临床诊断价值,可提高原发性肝癌检出率,并为早期临床治疗提供相关参考依据。
Objective To investigate the clinical value of carbohydrate antigen(CA199),alpha fetoprotein(AFP)and carcinoembryonic antigen(CEA)in the diagnosis of primary liver cancer. Methods Patients with primary liver cancer(n = 10)and patients with benign liver disease(n = 25)in the hospital from June,2017 to June,2018 were divided into two groups:hepatocellular carcinoma group and benign liver disease group. Healthy people of the same period(32 people)who received body examination in the hospital were regarded as the control group. Chemiluminescence method was used to detect subjects of 3 groups. The levels of CA199, AFP and CEA were compared among the 3 groups. Results Compared with the control group,the levels of CA199,AFP and CEA in HCC group were(125.42±23.57)U/mL,(821.26±62.46)ng/mL and(865.26±33.87)ng/mL respectively,which were significantly higher than those in the liver disease group and the control group(P<0.05). The sensitivity of combined detection of CA199,AFP and CEA was higher than that of single detection. The difference was statistically significant(P<0.05). Conclusion The combined diagnosis of CA199,AFP and CEA has high clinical value in the diagnosis of primary hepatocellular carcinoma. It can improve the detection rate of primary hepatocellular carcinoma,and provide reference for early clinical treatment.
作者
凌线峰
LING Xian-feng(Department of Laboratory,Luoyang City Eighth People’s Hospital,Luoyang,Henan,471003,China)
出处
《黑龙江医学》
2019年第2期158-159,共2页
Heilongjiang Medical Journal
关键词
糖类抗原
甲胎蛋白
癌胚抗原
肿瘤标志物
原发性肝癌
Carbohydrate antigen
Alpha-fetoprotein
Carcinoembryonic antigen
Tumor marker
Primary liver cancer